Earlier this month, at the American Society of Clinical Oncology annual meeting in Chicago, Onconova presented interim data from its Phase II ONTARGET study testing oral rigosertib as a single agent in transfusion-dependent, lower risk MDS patients

Earlier this month, shares of Clovis (NASDAQ:CLVS) more than doubled following the company's presentation of data on targeted EGFR inhibitor CO-1686 in non-small-cell lung cancer at the American Society of Clinical Oncology meeting in Chicago

Shares of Clovis (NASDAQ:CLVS), which jumped 100 percent earlier this month on data presented at the American Society of Clinical Oncology meeting in Chicago, closed Monday at $73.15, up $1.32. (See BioWorld Today, June 4, 2013

CHICAGO – At the American Society of Clinical Oncology (ASCO) annual meeting last week, there were plenty of individual trial results vying for attention

And More See BioWorld Today's extensive coverage of the American Society of Clinical Oncology meeting in Chicago

At the meeting of the American Society of Clinical Oncologists last week, BioMarin reported that its poly ADP-ribose polymerase inhibitor BMN 673 showed substantial single-agent antitumor activity in deleterious germline BRCA ovarian and breast cancers in an ongoing Phase I/II study in solid tumors

LONDON – Nanobiotix SA presented positive safety data from the first clinical study of NBTXR3, a nanoparticle drug that enhances the effects of radiotherapy on tumor cells without damaging healthy tissue, at the American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday

The following data were presented at the American Society of Clinical Oncology meeting in Chicago

CHICAGO – For those already cowed by the genetic diversity of cancer, Charles Swanton, of the Institute for Cancer Research/Royal Marsden Hospital, had some depressing news at the American Society for Clinical Oncology's (ASCO) annual meeting

And both reported results at the annual meeting of the American Society for Clinical Oncology over the weekend

While last year's American Society of Clinical Oncology (ASCO) meeting ended on cautiously encouraging advances in the cancer immunotherapy space, this year's meeting has put immunotherapy front and center, thanks in part to much-awaited data on and anti-PDL-1 and anti-PD-1 drugs from Roche AG and Bristol-Myers Squibb Co., respectively. (See BioWorld Today, June 6, 2012.) Those drugs, both check point inhibitors, generated significant buzz going into the ASCO meeting in Chicago

With all eyes focused on American Society of Clinical Oncology (ASCO) meeting in Chicago this week there will be plenty of news to keep investors engaged and it is expected that biotech will end the second quarter on a roll.

Piper Jaffray analyst Edward Tenthoff noted that not only is the ARRY-380 deal a positive for Array, but the FDA's approval of GlaxoSmithKline's MEK inhibitor (trametinib) for metastatic melanoma provides validation for Array's two partnered MEK programs, which are due to report data at the upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago

The data will be presented at the American Society of Clinical Oncology 2013 meeting in Chicago

The preladenant news was dwarfed by happier developments, such as the company's accelerated share repurchase valued at about $5 billion, the scheduling at an analyst meeting at the American Society of Clinical Oncology, and a favorable vote by an FDA advisory panel for suvorexant a first-in-class dual orexin receptor antagonist (DORA) for insomnia

Interim data from the solid tumors will be presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

completed an insider-based $21.6 million private placement, capping a fruitful week that included the full enrollment of a Phase IIb study of oncolytic cancer vaccine Pexa-Vec (JX-594, pexastimogene devacirepvec) in hepatocellular carcinoma (HCC), publication of clinical and preclinical data in Science Translational Medicine and release of three abstracts scheduled for presentation at the American Society of Clinical Oncology (ASCO) meeting next week in Chicago

The presentations will be made at the annual meeting of the American Society of Clinical Oncology in Chicago from May 31 through June 4

Interim data from that study were reported earlier and full data are expected to be presented at the upcoming American Society of Clinical Oncology meeting in Chicago